Mother, 35, discovers her cough that wouldn't shift is life-threatening LEUKAEMIA
Louise Moreton, from Melbourne, started feeling run-down after moving to Durham, England, with her husband and their son. She was quickly diagnosed with acute myeloid leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2019 Category: Consumer Health News Source Type: news

Genetic variations in a fourth gene linked to elevated leukemia risk in Hispanic children
(St. Jude Children's Research Hospital) Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2019 Category: Cancer & Oncology Source Type: news

Obesity Linked to Adverse Events in Children With Leukemia
WEDNESDAY, Feb. 13, 2019 -- For children with acute lymphoblastic leukemia (ALL), obesity is associated with an increased risk for adverse events during premaintenance chemotherapy, according to a study published in the February issue of Pediatric... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

New therapy for aggressive blood cancer discovered
(University of Veterinary Medicine -- Vienna) Researchers at Vetmeduni Vienna and Ludwig Boltzmann Institute for Cancer Research have identified a new therapeutic strategy for Acute Myeloid Leukemia. They found that the activity of the mutated oncogenic protein C/EBPα is dependent on MLL1 histone methyltransferase complex. Laboratory tests showed that functional perturbation of MLL1 complex led to death of AML cells with C/EBPα mutations. Inhibitor treatment released the differentiation block of cancer cells and restored normal maturation of blood cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2019 Category: International Medicine & Public Health Source Type: news

Role of the ALK Inhibitor AZD3463 in Sorafenib-Resistant Acute Myeloid Leukemia
Investigators evaluated whether  AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Drug compound could be next-generation treatment for aggressive form of leukemia
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society. (Source: World Pharma News)
Source: World Pharma News - January 28, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Drug compound could be next-generation treatment for aggressive form of leukemia
(Purdue University) Purdue University researchers are developing a series of drug compounds that have shown promise in treating acute myeloid leukemia, an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.About 30 percent of AML patients have a mutation caused by a kinase called FLT3, which makes the leukemia more aggressive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2019 Category: Cancer & Oncology Source Type: news

Allogeneic Transplants No Benefit in Hypodiploid ALL Allogeneic Transplants No Benefit in Hypodiploid ALL
Children with hypodiploid acute lymphoblastic leukemia, a rare form of the disease with a poor prognosis, have no survival benefit from allogeneic transplant and should not undergo it, say US doctors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Understanding the emergence of leukemia
(Instituto Gulbenkian de Ciencia) Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children. This blood cancer appears from the precursor cells that produce T lymphocytes (a type of white blood cells). A new study from Instituto Gulbenkian de Ciencia, conducted in mice, shows that leukemia can emerge as a consequence of prolonging the presence of precursor cells in the thymus. This work was now published in the scientific journal The Journal of Immunology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2019 Category: Cancer & Oncology Source Type: news

Addition of BMT Not Indicated in Some With Peds Hypodiploid ALL
WEDNESDAY, Jan. 23, 2019 -- For some children with hypodiploid acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation does not improve outcomes compared with chemotherapy alone, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia TH... Biopharmaceuticals, Oncology, Regulatory Amgen, BLINCYTO, blinatumomab, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2019 Category: Pharmaceuticals Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remissi...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

No substantial benefit from transplantation reported for a high-risk leukemia subtype
(St. Jude Children's Research Hospital) Study led by St. Jude Children's Research Hospital found treatment guided by measuring minimal residual disease was associated with better outcomes for hypodiploid acute lymphoblastic leukemia patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2019 Category: Cancer & Oncology Source Type: news

WATCH: How one mom turned grief into action
Robin Roberts' highlights the work of a mother who lost her 9-year-old son to acute myeloid leukemia in 2014 and how she is turning her grief into action as part of her "Thriver Thursday" series. (Source: ABC News: Health)
Source: ABC News: Health - January 17, 2019 Category: Consumer Health News Tags: GMA Source Type: news

The Emerging Profile of Immunotherapy Approaches in the Treatment of AML
Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2019 Category: Cancer & Oncology Authors: Naval Daver, MD Source Type: news

Killer blows? Knockout study of pair of mouse MicroRNA provides cancer insight
(Tokyo Medical and Dental University) Tokyo Medical and Dental University (TMDU) researchers used knockout mouse models created by gene editing to reveal that the miRNA miR-146b, like miR-146a, is involved in the development of cancers, with them having similar but not identical effects. The knockout mice showed high rates of B-cell lymphoma and acute myeloid leukemia, which was associated with the absence of miRNA causing NF-κB overactivation. These insights should help in the fight against cancers involving miRNA dysregulation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 17, 2019 Category: Biology Source Type: news

Young dad thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at  Ronald Reagan UCLA Medical Center.  “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say ...
Source: UCLA Newsroom: Health Sciences - January 17, 2019 Category: Universities & Medical Training Source Type: news

Father of two thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at  Ronald Reagan UCLA Medical Center.  “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say ...
Source: UCLA Newsroom: Health Sciences - January 16, 2019 Category: Universities & Medical Training Source Type: news

Is the Revised ELN Classification More Accurate for Acute Myeloid Leukemia?
A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML. (Source: CancerNetwork)
Source: CancerNetwork - January 14, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Family of a cancer-stricken girl have sparked up a friendship with the 'angel' who saved her life
Skylah Ballentine-Brain, now eight, was diagnosed with acute lymphoblastic leukaemia at less than one-year-old, while her family were living in Cape Town. She was forced to endure chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2019 Category: Consumer Health News Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
FRIDAY, Jan. 4, 2019 -- The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) are elevated after chemotherapy use for solid tumors, according to a study published online Dec. 20 in JAMA Oncology. Lindsay M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2019 Category: Pharmaceuticals Source Type: news

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel® (dasatinib) tablets to include the treatment of pediatric patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 2, 2019 Category: Drugs & Pharmacology Source Type: news

HEALTH NOTES: Ellie Mae stars as Santa after beating cancer  
Ellie Mae Wile-Dunne (pictured), who was diagnosed with the the blood cancer acute lymphoblastic leukaemia when she was four, is starring in cancer charity CLIC Sargent ’s online ad. (Source: the Mail online | Health)
Source: the Mail online | Health - December 22, 2018 Category: Consumer Health News Source Type: news

FDA Approves Two New Drugs for ALL and BPDCN FDA Approves Two New Drugs for ALL and BPDCN
The FDA has granted approval for a drug to be used in acute lymphoblastic leukemia and the first treatment approved for blastic plasmacytoid dendritic cell neoplasm.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves New Enzyme Product for ALL FDA Approves New Enzyme Product for ALL
The FDA has granted approval for a new enzyme product, calaspargase pegol-mknl, to be used in acute lymphoblastic leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2018 Category: Drugs & Pharmacology Source Type: news

Study finds elevated risk of rare blood cancers after chemotherapy for most solid tumors
(NIH/National Cancer Institute) Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study was published December 20, 2018, in JAMA Oncology. NCI is part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2018 Category: Cancer & Oncology Source Type: news

First Hedgehog Pathway Inhibitor Approved in AML Patients
Clinicians now have a new treatment to offer elderly patients with newly diagnosed acute myeloid leukemia who have comorbidities that preclude the use of intensive chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Newly Approved Agent Fills Gap in Therapy for High-Risk AML
The US Food and Drug Administration recently approved a new agent for  treatment of adult patients with relapsed or refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

NSU researchers uncover genetic marker, predictor of early relapse in pediatric ALL
(Nova Southeastern University) Researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia (ALL) patients. This (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2018 Category: Cancer & Oncology Source Type: news

Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Potential seen for tailoring treatment for acute myeloid leukemia
(University of Washington Health Sciences/UW Medicine) Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2018 Category: Cancer & Oncology Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Screening LSCs For AML Drug Resistance, Sensitivity
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Allogeneic Transplantation in Elderly AML Patients
Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA Warns About Serious Adverse Effect of AML Drug Enasidenib FDA Warns About Serious Adverse Effect of AML Drug Enasidenib
A life-threatening adverse effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Warns About Dangerous Side Effect of AML Drug Enasidenib FDA Warns About Dangerous Side Effect of AML Drug Enasidenib
A life-threatening side effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Treatment for AML Patients With Gene Mutation
THURSDAY, Nov. 29, 2018 -- Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation, the agency announced in a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news

Wendy Atkin obituary
Epidemiologist whose research led to a breakthrough in bowel cancer screening programmes worldwide“Breakthrough” is an overused word when applied to medical advances. But in the case of the2010 trial of a new screening test for bowel cancer led by Wendy Atkin, professor of gastrointestinal epidemiology atImperial College London, who has died of acute myeloid leukaemia aged 71, it is fully deserved. Its impact will be felt by millions. The trial was the first in the world to show that bowel cancer – the second biggest cancer killer in the UK – could be prevented with a simple, five-minute test.The ex...
Source: Guardian Unlimited Science - November 29, 2018 Category: Science Authors: Ara Darzi Tags: Cancer research Health Medical research Science Source Type: news

Venetoclax combination approved for elderly AML
(Dana-Farber Cancer Institute) Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.But a new option -- a combination of a standard drug and the novel agent venetoclax -- has been granted accelerated approval by the Food and Drug Administration for such patients after a large, multicenter phase 1 clinical trial showed the combination had 'promising efficacy' and was well tolerated in older AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia
The FDA's approval is for the first drug targeting FLT3 mutations in AML.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Single-Agent FLT3 Inhibitor Gets FDA Nod for Acute Leukemia
(MedPage Today) -- First monotherapy OK'd for relapsed or refractory patients with FLT3 mutation (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 28, 2018 Category: Hematology Source Type: news

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
November 28, 2018 -- The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation
The FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: World Pharma News)
Source: World Pharma News - November 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new targeted drug for leukemia tested at University of Pennsylvania
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
(University of Colorado Anschutz Medical Campus) Clinical trial results published in the journal Nature Medicine and being presented this weekend at the American Society for Hematology Annual Meeting show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news